Science
Rademikibart misses primary endpoint Hopes for a Dupixent challenger hit a setback

Connect Biopharma’s asthma drug rademikibart failed to meet the primary endpoint in a Phase 2 trial. The news sent the company’s shares sharply lower.
According to U.S. biotech publication Fierce Biotech on the 16th (local time), Connect Biopharma said rademikibart, an interleukin (IL)-4/IL-13 blocker, failed to meet the primary endpoint in a Phase 2 asthma trial.
The midstage trial enrolled 160 patients with asthma and type 2 inflammation, who received rademikibart by subcutaneous injection or placebo.
Over 28 days, rademikibart reduced the treatment failure rate by 66% compared with placebo. However, the result was not sufficient to demonstrate statistical significance. The company said, “The overall treatment failure rate was lower than initially expected.”
The company emphasized that the trial showed positive signals on secondary endpoints. Forced expiratory volume in 1 second (FEV1) after administration of a bronchodilator improved significantly from baseline, it said. FEV1 is a breathing test that measures the amount of air a person can forcefully exhale in the first second after taking a deep breath.
The failure came shortly after a Phase 3 trial of rademikibart for atopic dermatitis in China was reported to have succeeded. Partner Simcere Pharmaceutical announced the results in March. San Diego-based Connect Biopharma plans to release results later this month from another Phase 2 trial in patients with chronic obstructive pulmonary disease (COPD).
Barry Quart, Connect Biopharma’s CEO, said, “These results support rademikibart’s potential to meaningfully improve patient outcomes during an important period following an exacerbation.” He added, “The full results of this study provide a clear road map for designing a Phase 3 program.”
Investors were not reassured. Connect Biopharma shares fell 35% from the previous day’s closing price of $1.73 to $1.12 within the first hour of trading.
Rademikibart is an anti-interleukin-4 receptor alpha (IL-4Rα) antibody that blocks receptor binding needed to activate signaling pathways that trigger asthma. Simcere Pharmaceutical secured the drug’s rights in China and paid $21 million upfront. Rademikibart has drawn attention as a potential challenger to Dupixent, Sanofi and Regeneron’s blockbuster asthma and COPD drug.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Blocking Disease Proteins With ‘Molecular Gates’ … Gate Bioscience Prepares to Enter the Clinic

Rezolute Meets Phase 3 Goal in Tumor Hyperinsulinism, Shares Rise Ahead of FDA Meeting

Regeneron’s POTS drug succeeds in Phase 2; Phase 3 to begin in first half of next year

Egene Receives Approval to Amend Phase 2/3 Trial of Quadrivalent Meningococcal Vaccine

GC Biopharma Develops Korea’s First Generative AI Drug Safety Monitoring Software, Focused on Preventing Missed Cases

Daewoong Pharmaceutical Wins Phase 1 Approval for Drug to Regenerate Intestinal Mucosa: “Beyond Immunosuppression”